|
Daphnia magna metabolite
|
CHEBI_83056 |
|
|
central nervous system stimulant
|
CHEBI_35337 |
|
|
central nervous system drug
|
CHEBI_35470 |
|
|
splenic marginal zone lymphoma
|
DOID_0050750 |
|
|
marginal zone B-cell lymphoma
|
DOID_0050748 |
|
|
eukaryotic initiation factor 4F inhibitor
|
CHEBI_137079 |
|
|
serotonin uptake inhibitor
|
CHEBI_50949 |
|
|
second generation antipsychotic
|
CHEBI_65191 |
|
|
antipsychotic agent
|
CHEBI_35476 |
|
|
H2-receptor antagonist
|
CHEBI_37961 |
|
|
ataxia with oculomotor apraxia type 2
|
DOID_0050755 |
|
|
first generation antipsychotic
|
CHEBI_65190 |
|
|
deafness-dystonia-optic neuronopathy syndrome
|
DOID_0050757 |
|
|
myotonic dystrophy type 2
|
DOID_0050759 |
|
|
sialyltransferase inhibitor
|
CHEBI_62915 |
|
|
axin stabilizer
|
CHEBI_62914 |
|
|
mastitis
|
DOID_10690 |
|
|
paragonimiasis
|
DOID_10699 |
|
|
chronic endophthalmitis
|
DOID_10697 |
|
|
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
|
CHEBI_62913 |
|
